March 10, 2025

NRG Oncology Broadcast archives are accessible from our website at any time. Please bookmark this link for your convenience.

NRG Leadership and Committee Openings are now

Centrally Located on our website!

NRG Oncology is seeking candidates for the following:

• Head & Neck Cancer Committee Surgical Vice Chair
• Imaging Committee Chair
• Lung Cancer Committee Chair

Applications DUE APRIL 7, 2025 - Read more here  

ACTIVATION

GENITOURINARY

NRG-GU014: Open to patient entry effective March 7, 2025. (posted on CTSU)

OTHER PROTOCOL NOTICES

1. ALL DISEASE SITES

NRG-GY022: Reminder: Actively Recruiting MALE Patients only Read More

2. BIOSPECIMEN BANKS

Printing Biospecimen Transmittal PDFs from Rave

Please note an effort is underway to clarify how to obtain a Biospecimen Transmittal PDF for submission to the NRG Oncology Biospecimen Bank. Read More

3. BRAIN

NRG-BN011: The central pathology form (P4) was updated on November 4, 2024. Please ensure you are using the current version of the form for tissue submissions.

NRG-BN014: An updated Biospecimen Collection and Submission Manual (version date March 7, 2025) is posted on CTSU.

4. BREAST

NRG-BR008/HERO: Study webinars are being held via Microsoft Teams on March 24th at 3pm ET and March 26th at 11am ET. Please see the memorandum, dated February 24, 2025, (posted on CTSU) for details and how to register for one of the sessions. Please note: Google Chrome is the preferred browser to register for the webinars.

5. CANCER PREVENTION & CONTROL

NRG-CC005/FORTE: Forte Fridays newsletter

NRG-CC010: The study is open to NRG sites in Japan and South Korea. The optional biospecimen collection does not apply to sites participating in these countries.

6. GYNECOLOGIC

NRG-GY026: Please note, the post-chemo cfDNA Whole Blood (WB03) should only be collected if the Pre-Treatment cfDNA Whole Blood (WB01) was collected.

NRG-GY031: Please note, there is an error in the section 4.2 table and the Biospecimen Collection and Submission Manual. The Part I PK collection is to be done on Cycle 1, Day 1, and Cycle 1, Day 8. This will be updated with the next amendment.

7. HEAD & NECK

NRG-HN008 - Reminder: please update treatment and AE data weekly. This is a Phase I trial and timely data submission is very important. 

NRG-HN014: An updated Biospecimen Collection and Submission Manual (version date March 7, 2025) is posted on CTSU. Biospecimen codes were corrected to match Section 10 of the current protocol (version date: September 23, 2024). Please use the corrected codes effective immediately.

8. LUNG

S1914: A memorandum has been posted to CTSU regarding termination of QOL instructing sites to discontinue administration as of February 1, 2025. All delinquent QOL data up until this date is to be entered into Rave for S1914-E-01. Please review all cases at your site for completion. 

9. VTOC TRAINING

The VTOC Webinar Training Series schedule and registration is available for NRG Oncology Research Associates working on NRG-BN014, NRG-BR009, NRG-CC003, NRG-CC005, NRG-CC011, NRG-CC013, NRG-HN001, NRG-HN002, and NRG-HN014. Space is limited so register now and reserve your seat. The next webinar training is scheduled for March 12, 2025.

Drug Safety and Investigator’s Brochure (IB*) updates have been issued for the following studies:

*The current version of the Investigator Brochure Documents for Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI)-sponsored trials are available for access via the Cancer Therapy Evaluation Program (CTEP) Agent Inventory Management System (AURORA) application. Log-in using your Identity and Access Management (IAM) or ID.me credentials and provide the requested information to access the document.

Every site principal investigator is responsible for reviewing this document. The Investigator Brochure is for use by the site principal investigator and any study personnel under his/her supervision who need to know the contents for the conduct of a clinical trial, including Institutional Review Board(s) or Independent Ethics Committee(s).

1. NRG leadership and committee openings are now centrally located on our website at https://www.nrgoncology.org/Current-Openings

NRG Oncology is seeking candidates for the following:

• Head & Neck Cancer Committee Surgical Vice Chair
• Imaging Committee Chair
• Lung Cancer Committee Chair

Applications DUE APRIL 7, 2025 - Read more

2. NRG Oncology GYN Cancer Committee is Requesting Proposals

Submit your proposals in advance of the April 11, 2025 Interim Meeting.

Proposals DUE March 12, 2025 - Read more

3. NRG Member Information Form

We are excited to introduce the NRG Member Information Data Collection Initiative that will allow us to create a comprehensive member database, enabling us to better understand and serve our members. Your information will be kept secure and confidential, ensuring that your privacy is always protected. All members are encouraged to complete the form or indicate that they wish to opt out of this data collection initiative. 

Scan the QR code below or click this link to access the form. 

Questions? Read more here

NRG Oncology is pleased to report the scientific articles that appeared during the previous week. This publications report includes links, when available, to the article, PubMed abstract, or association abstract.

PUBLISHED ARTICLES

Dressler EV, Pugh SL, Gunn HJ, Unger JM, Zahrieh DM, Snavely AC. Practical design considerations for cluster randomized controlled trials: lessons learned in community oncology research. J Natl Cancer Inst Monogr. 2025 Mar 1;2025(68):56-64. doi: 10.1093/jncimonographs/lgae053. PMID: 39989035; PMCID: PMC11848037. Read more.

Enserro DM, Gunn HJ, Elsaid MI, Duan F, Pugh SL. Challenges to and considerations of designing cancer prevention trials. J Natl Cancer Inst Monogr. 2025 Mar 1;2025(68):49-55. doi: 10.1093/jncimonographs/lgae044. PMID: 39989045; PMCID: PMC11848038. Read more.

Hu P, Steingrimsson JA, Cole E, Cormack J, Dunn BK, Gatsonis C, Lee C, Li N, Pisano ED, He J, Kramer BS. Design considerations and challenges in the CHinA National CancEr Screening (CHANCES) trial and Tomosynthesis Mammographic Imaging Screening Trial (TMIST). J Natl Cancer Inst Monogr. 2025 Mar 1;2025(68):42-48. doi: 10.1093/jncimonographs/lgae049. PMID: 39989037; PMCID: PMC11848039. Read more.

Izmirlian G, Sirota LA, Berger VW, Kipnis V. The fundamentals of multiplicity adjustment in biostatistics. J Natl Cancer Inst Monogr. 2025 Mar 1;2025(68):10-13. doi: 10.1093/jncimonographs/lgae050. PMID: 39989036; PMCID: PMC11848033. Read more.

Mazza GL, Culakova E, Enserro DM, Dignam JJ, Unger JM. Design and analysis considerations for investigating patient subgroups of interest within cancer clinical trials. J Natl Cancer Inst Monogr. 2025 Mar 1;2025(68):22-29. doi: 10.1093/jncimonographs/lgae045. PMID: 39989043; PMCID: PMC11848030. Read more.

Monge C, Eldridge L, Pearlman PC, Venkatesh V, Tregear M, Loehrer PJ Sr, Galassi A, Gopal S, Ginsburg O. Global perspectives on patient-centered outcomes: advancing patient-centered cancer clinical trials globally. J Natl Cancer Inst Monogr. 2025 Mar 1;2025(68):35-41. doi: 10.1093/jncimonographs/lgae043. PMID: 39989041; PMCID: PMC11848040. Read more.

Nuño MM, Pugh SL, Ji L, Piao J, Dignam JJ, Steingrimsson JA. On the use of external controls in clinical trials. J Natl Cancer Inst Monogr. 2025 Mar 1;2025(68):30-34. doi: 10.1093/jncimonographs/lgae046. PMID: 39989040; PMCID: PMC11848027. Read more.

Pugh SL, Lee C, Dunn BK, Dignam JJ. The importance of patient-centered research in oncology clinical trials: motivation for the Monograph series. J Natl Cancer Inst Monogr. 2025 Mar 1;2025(68):1-2. doi: 10.1093/jncimonographs/lgae052. PMID: 39989042; PMCID: PMC11848026. Read more.

Snavely AC, Gunn HJ, Lee JW, Pugh SL, Barlow WE, Culakova E, Arnold KB, Kittel CA, Smith S, Hanlon BM, Tan AD, Dockter T, Zahrieh D, Dressler EV. Intracluster correlation coefficients from cluster randomized trials conducted within the NCI Community Oncology Research Program (NCORP). J Natl Cancer Inst Monogr. 2025 Mar 1;2025(68):65-72. doi: 10.1093/jncimonographs/lgae048. PMID: 39989039; PMCID: PMC11848034. Read more.

Unger JM, Mazza GL, Elsaid MI, Duan F, Dressler EV, Snavely AC, Enserro DM, Pugh SL. When to adjust for multiplicity in cancer clinical trials. J Natl Cancer Inst Monogr. 2025 Mar 1;2025(68):3-9. doi: 10.1093/jncimonographs/lgae051. PMID: 39989044; PMCID: PMC11848029. Read more.

Please note the following upcoming meetings and abstract submission deadlines

UPCOMING MEETINGS

American Association for Cancer Research (AACR); Apr 25-30, 2025; Chicago, IL

American Association for Thoracic Surgery (AATS); May 2-5, 2025; Seattle, WA

American Brachytherapy Society (ABS); Jun 18-21, 2025; Nashville, TN

American College of Radiology (ACR); May 3-7, 2025; Washington, DC

American Head & Neck Society (AHNS); May 14-15, 2025; New Orleans, LA

American Radium Society (ARS) Annual Meeting; Apr 3-6, 2025; Seattle, WA

American Surgical Association (ASA); Apr 24-26, 2025; San Diego, CA

American Society of Breast Surgeons (ASBrS); Apr 30-May 4, 2025; Las Vegas, NV

American Society of Clinical Oncology (ASCO); May 30-Jun 3, 2025; Chicago, IL

American Society of Colon and Rectal Surgeons (ASCRS); May 11-14, 2025; San Diego, CA

Canadian Association of Radiation Oncology (CARO); Sep 10-13, 2025; Calgary, AB

Society for Clinical Trials (SCT); May 18-21, 2025; Vancouver, BC

Society for Gynecologic Oncology (SGO); Mar 14-17, 2025; Seattle, WA

Society of Surgical Oncology (SSO) Annual Meeting; Mar 27-29, 2025; Tampa, FL

St. Gallen Breast Cancer Conference; Mar 12-15, 2025; Vienna Austria

UPCOMING ABSTRACT SUBMISSION DEADLINES

AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; Sep 18-21, 2025; Baltimore, MD; Due to publications committee Jun 10, 2025; Submission deadline Jun 24, 2025, 1:00 pm ET

American Society for Radiation Oncology (ASTRO); Sep 28-Oct 1, 2025; San Francisco, CA; LBA Jul 10, 2025, 11:59 pm PT

European Society for Medical Oncology (ESMO); Oct 17-21, 2025; Berlin, Germany; Due to publications committee Apr 25, 2025; Submission deadline May 13, 2025, 21:00 CET; LBA Sep 9, 2025, 21:00 CET (placeholder required)

ESMO Breast Cancer; May 14-16, 2025; Munich, Germany; LBA Apr 15, 2025, 21:00 CET (placeholder required)

ESMO Gastrointestinal Cancers; Jul 2-5, 2025; Barcelona, Spain; Due to publications committee Mar 25, 2025; Submission deadline Apr 8, 2025, 21:00 CET; LBA Jun 5, 2025, 21:00 CET (placeholder required)

ESMO Gynaecological Cancers; Jun 19-21, 2025; Vienna, Austria; Due to publications committee Mar 18, 2025; Submission deadline Apr 1, 2025, 21:00 CET

European Society for Radiotherapy and Oncology (ESTRO); May 2-6, 2025; Vienna, Austria; LBA Mar 19, 2025

International Gynecologic Cancer Society (IGCS); Nov 5-7, 2025; Cape Town, South Africa; Due to publications committee Apr 21, 2025; Submission deadline May 5, 2025, 23:59 SAST; LBA Sep 29, 2025 (placeholder required)

International Society for Quality-of-Life Research (ISOQOL); Oct 22-25, 2025; Milwaukee, WI; Due to publications committee Mar 25, 2025; Submission deadline Apr 7, 2025

Radiological Society of North America (RSNA); Nov 30-Dec 4, 2025; Chicago, IL; Due to publications committee Apr 23, 2025; Submission deadline May 7, 2025, Noon CT



Western Association of Gynecologic Oncologists (WAGO); Jun 18-21, 2025; Colorado Springs, CO; Due to publications committee Mar 5, 2025; Submission deadline Mar 19, 2025, 11:59 pm PT